Sera Prognostics to Present PRIME Study Results at 2025 SMFM Pregnancy Meeting

SALT LAKE CITY, Dec. 4, 2024 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the results of the PRIME study were accepted as a late-breaking abstract for oral podium presentation at the Society for Maternal-Fetal Medicine 2025 Pregnancy Meeting™ on January 31, 2025 at 10:15 a.m. MT. Dr. Brian Iriye – maternal-fetal medicine exp ...